Alzheimer’s disease (AD) genetics has long focused on autosomes, with landmark findings such as APOE ε4 and numerous autosomal loci shaping our understanding of risk and biology. Yet, one key piece of the genomic puzzle — the X chromosome — has remained largely unexamined due to analytical challenges inherent in its biology. A new large-scale X-chromosome-wide association study (XWAS) now reveals that the X chromosome harbors novel genetic variation associated with AD risk, expanding our view of AD heritability and molecular pathways.
Why the X Chromosome Matters in AD
Although the X chromosome constitutes ~5 % of the human genome, it has been systematically excluded from most genome-wide association studies due to technical complexities — including sex differences in dosage (hemizygosity in males), X-inactivation patterns in females, and variant calling challenges. Importantly, the X chromosome contains a high proportion of genes that are expressed in the brain, making it a biologically plausible source of unexplored AD genetic risk.
Sex differences in AD prevalence — with women disproportionately affected — further motivate investigation of X-linked variation and gene expression dynamics beyond traditional autosomal analyses.
Study Design: First Large-Scale XWAS in Alzheimer’s Disease
A consortium of international cohorts — including the Alzheimer’s Disease Genetics Consortium (ADGC), Alzheimer’s Disease Sequencing Project (ADSP), UK Biobank, FinnGen, and the U.S. Million Veterans Program — was meta-analyzed using over 1.15 million participants of European ancestry (≈57–58 % female; 138,558 AD cases). Case-control logistic regression models evaluated genetic variants on the X chromosome for association with AD risk.
Key analytical features included:
X-chromosome–wide thresholds (P < 1 × 10⁻⁵) and genome-wide thresholds (P < 5 × 10⁻⁸) tailored to the X chromosomal context.
Colocalization analyses with gene expression QTLs in brain and non-brain tissues, linking association signals to putative functional genes.
Key Findings: Novel Genetic Loci Including SLC9A7
Six independent X-linked loci reached significance at the X-chromosome–wide level, with four showing evidence of expression colocalization — suggesting likely functional relevance to AD biology.
1. SLC9A7: A Genome-Wide Significant X-Linked Risk Locus
The most robust finding centered on a variant within an intron of SLC9A7, reaching genome-wide significance for association with AD risk. Colocalization analyses prioritized both SLC9A7 and the nearby CHST7 locus.
Gene Function: SLC9A7 (also known as NHE7) encodes a Na⁺/H⁺ exchanger that regulates pH homeostasis in Golgi secretory compartments and endosomes — key organelles in protein trafficking and processing.
Alzheimer’s Relevance: Dysregulated endosomal–Golgi pH may impact amyloid precursor protein (APP) processing, amyloid-β accumulation, and cellular clearance pathways. This aligns with growing evidence implicating endosomal–lysosomal dysfunction as an early event in AD pathophysiology.
The observed risk increase at this locus was modest (e.g., odds ratios ~1.03–1.05), consistent with the polygenic nature of late-onset AD.
Other X-Linked Signals and X-Inactivation Biology
In addition to SLC9A7, the study identified multiple loci with evidence of gene expression associations in both brain and non-brain tissues, suggesting possible pathways that require further mechanistic interrogation.
Interestingly, four of the six loci showed evidence of escape from X-chromosome inactivation (XCI). XCI — the epigenetic silencing of one X chromosome in females — complicates genetic modeling, but loci escaping inactivation may contribute to dose differences between sexes, potentially informing sex-specific risk profiles.
Interpreting the Findings: Mechanistic and Clinical Implications
Biology of pH Regulation and Amyloid Biology
The involvement of SLC9A7 underscores Golgi/endosomal pH regulation as a candidate pathway influencing amyloidogenic processing. Dysregulated pH in these compartments affects enzymes such as β- and γ-secretases and could alter trafficking of APP and amyloid-β peptides.
Sex-Specific Risk Considerations
X-linked genetic variation and patterns of X-inactivation escape may underlie or modulate sex differences in AD risk and progression, offering a substrate for future sex-stratified genetic analyses and therapeutic stratification.
Limitations and Future Directions
Ancestry Focus: The current analysis was limited to individuals of European descent, underscoring the need for global multi-ancestry studies to ensure genetic insights are broadly applicable.
Functional Validation Needed: While colocalization suggests putative causal genes, experimental validation (e.g., cellular models, CRISPR perturbations) is required to confirm mechanisms.
Sex-Stratified and Rare Variant Analyses: Larger cohorts and integrative omics (epigenetics, transcriptomics, proteomics) will be crucial to unravel sex-specific effects and the role of rare X-linked variants.
Where This Advances the Field
This study is the first robust investigation of the X chromosome in Alzheimer’s disease genetics, expanding beyond traditional autosomal GWAS. By identifying novel X-linked risk loci — particularly SLC9A7 — it opens new avenues for research into endosomal–Golgi dysfunction, sex-specific genetic effects, and potential therapeutic targets.